Study Evaluation LXR-623 in Healthy Adults

Wyeth

Status and phase: Terminated; Phase 1

Conditions: Healthy Subjects

Treatments: Drug: LXR-623

Study type: Interventional

Funder types: Industry

Identifiers

NCT00379860

3201A1-101

Details and patient eligibility

About

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Generally healthy adults.
• Liver function tests, triglycerideres, and creatinine must be below upper limit of normal at screening.

Exclusion criteria

• A history or active presence of clinically important medical disease.
• Any metal implants or devices.
• Claustrophobia.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind